Impact of Peritoneal Dialysis Solutions on Outcomes

Evidence-Based Nephrology

Volumn , Issue , 2009, Pages 500-508

  Johnson, David W ^a   Williams, John D ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Amino acid dialysates; Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry; Chronic Kidney Disease Stage 5 PD; Dialysate effluent concentrations of CA125; Icodextrin starch derived, high molecular weight glucose polymer; Impact of PD solutions on outcomes; Neutral pH, lactate buffered, low GDP fluids

Indexed keywords

EID: 84861662210     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303391.ch46     Document Type: Chapter

References (82)

1. Serkes KD, Blagg CR, Nolph KD, Vonesh EF, Shapiro F. Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis:a multicenter study. Perit Dial Int 1990; 10: 15-19.
2. Vonesh EF, Moran J. Mortality in end-stage renal disease:a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1999; 10: 354-365.
3. Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P et al. Hemodialysis versus peritoneal dialysis:a comparison of adjusted mortalityrates. Am J Kidney Dis 1997; 30: 334-342.
4. Tanna MM, Vonesh EF, Korbet SM. Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting. Am J Kidney Dis 2000; 36: 1175-1182.
5. Blake PG. Integrated end-stage renal disease care:the role of peritoneal dialysis. Nephrol Dial Transplant 2001; 16(Suppl 5): 61-66.
6. Davies SJ, Van Biesen W, Nicholas J, Lameire N. Integrated care. Perit Dial Int 2001; 21(Suppl 3): S269-S274.
7. Johnson DW, McDonald SP, Excell L, Livingston B, Shtangey V. Peritoneal dialysis. In:McDonald SP, Excell L, editors, ANZDATA Registry Report 2005. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, South Australie, 2006; 84-100.
8. Topley N. Membrane longevity in peritoneal dialysis:impact of infection and bio-incompatible solutions. Adv Ren Replace Ther 1998; 5: 179-184.
9. Pecoits-Filho R, Stenvinkel P, Heimburger O, Lindholm B. Beyond the membrane:the role of new PD solutions in enhancing global biocompatibility. Kidney Int Suppl 2003; 2003: S124-S132.
10. Witowski J, Jorres A. Effects of peritoneal dialysis solutions on the peritoneal membrane:clinical consequences. Perit Dial Int 2005; 25(Suppl 3): S31-S34.
11. Topley N. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Perit Dial Int 1997; 17: 42-47.
12. Schambye HT. Effect of different buffers on the bio compatibility of CAPD solutions. Perit Dial Int 1996; 16(Suppl 1): S130-S136.
13. Nau B, Schmitt CP, Almeida M, Arbeiter K, Ardissino G, Bonzel KE et al. BIOKID:randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children. BMC Nephrol 2004; 5: 14.
14. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
15. Dobbie JW, Anderson JD, Hind C. Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 1994; 14(Suppl 3): S16-S20.
16. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions:Effects on the peritoneal membrane. Kidney Int 2004; 66: 1257-1265.
17. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2005; 67: 1559-1565.
18. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182-186.
19. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 1999; 14: 1541-1549.
20. Jorres A, Gahl GM, Topley N, Neubauer A, Ludat K, Muller C et al. In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. Nephrol Dial Transplant 1994; 9: 785-790.
21. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C et al. The Euro-Balance Trial:the effect of a newbiocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418.
22. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357.
23. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U et al. Glucose degradation products in PD fluids:do they disappear from the peritoneal cavityand enter the systemic circulation? Kidney Int 2003; 63: 298-305.
24. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-255.
25. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR et al. Changing prescribing practice in CAPD patients in Korea:increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21: 2893-2899.
26. Haag-Weber M, Haug U, Weislander A, Nabut J, Deppish R. Decline of residual renal function in peritoneal dialysis patients depends on uptake of carbonyl compounds from the peritoneal cavity:first data of a prospective clinical trial. J Am Soc Nephrol 2003; 14: 476A.
27. Fan SLS, Pile T, Punzalan S, Raftery M, Yaqoob MM. Prospective randomised controlled trial of biocompatible PD solutions in incident PD patients:interim analysis. J Am Soc Nephrol 2006; 17: 279A.
28. Brown F, Johnson DW. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients. Perit Dial Int 2006; 26: 112-113.
29. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001; 21(Suppl 3): S102-S107.
30. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-1538.
31. Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD:a prospective, randomized study. Nephrol Dial Transplant 2004; 19: 2101-2106.
32. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003; 14: 2632-2638.
33. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53: 1061-1067.
34. Rippe B, Simonsen O, Wieslander A, Landgren C. Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int 1997; 17: 27-34.
35. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution:clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20: 516-523.
36. Carrasco AM, Rubio MA, Sanchez Tommero JA, Fernandez GF, Gonzalez RM, del Peso GG et al. Acidosis correction with a new 25 mmol/l bicarbonate/15 mmol/l lactate peritoneal dialysis solution. Perit Dial Int 2001; 21: 546-553.
37. le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients:a randomized crossover study. Adv Perit Dial 2004; 20: 170-176.
38. Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54: 1731-1738.
39. Coles GA, O'Donoghue DJ, Pritchard N, Ogg CS, Jani FM, Gokal R et al. A controlled trial of two bicarbonate-containing dialysis fluids for CAPD:final report. Nephrol Dial Transplant 1998; 13: 3165-3171.
40. Simonsen O, Sterner G, Carlsson O, Wieslander A, Rippe B. Improvement of peritoneal ultrafiltration with peritoneal dialysis solution buffered with bicarbonate/lactate mixture. Perit Dial Int 2006; 26: 353-359.
41. Montenegro J, Saracho RM, Martinez IM, Munoz RI, Ocharan JJ, Val-ladares E. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26: 89-94.
42. Rubin J, Klein E, Jones Q, Planch A, Bower J. Evaluation of a polymer dialysate. Trans Am Soc Artif Intern Organs 1983; 29: 62-66.
43. Peers E, Gokal R. Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume. Artif Organs 1998; 22: 8-12.
44. Coles GA. Biocompatibilityand new fluids. Perit Dial Int 1999; 19(Suppl 2): S267-S270.
45. Garcia-Lopez E, Lindholm B, Tranaeus A. Biocompatibility of new peri-tonealdialysis solutions:clinicalexperience. Perit Dial Int 2000; 20(Suppl 5): S48-S56.
46. Chung SH, Stenvinkel P, Bergstrom J, Lindholm B. Biocompatibility of new peritoneal dialysis solutions:what can we hope to achieve? Perit Dial Int 2000; 20(Suppl 5): S57-S67.
47. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46: 496-503.
48. Posthuma N, ter Weel PM, Verbrugh HA, Oe PL, Peers E, Sayers J et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12: 550-553.
49. Plum J, Gentile S, Verger C, Brunkhorst R, Bahner U, Faller B et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39: 862-871.
50. Wolfson M, Piraino B, Hamburger RJ, Morton AR. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40: 1055-1065.
51. Woodrow G, Stables G, Oldroyd B, Gibson J, Turney JH, Brownjohn AM. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Nephrol Dial Transplant 1999; 14: 1530-1535.
52. Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, Hiralall JK, de Waart DR, Struijk DG et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50: 979-986.
53. Wiggins KJ, Rumpsfeld M, Blizzard S, Johnson DW. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure. Nephrology (Carlton) 2005; 10:33-36.
54. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16: 546-554.
55. Gokal R, Mistry CD, Peers EM. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Perit Dial Int 1995; 15: 226-230.
56. Ota K, Akiba T, Nakao T, Nakayama M, Maeba T, Park MS et al. Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients. Perit Dial Int 2003; 23: 356-361.
57. Posthuma N, ter Weel PM, Donker AJ, Peers EM, Oe PL, Verbrugh HA. Icodextrin use in CCPD patients during peritonitis:ultrafiltration and serum disaccharide concentrations. Nephrol Dial Transplant 1998; 13: 2341-2344.
58. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters:a randomized study. Kidney Int 2003; 63: 1556-1563.
59. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC et al. Icodextrin improves the fluid status of peritoneal dialysis patients:results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344.
60. Mujais S, Nolph K, Gokal R, Blake P, Burkart J, Coles G et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4): S5-S21.
61. de Boer AW, Schroder CH, van Vliet R, Willems JL, Monnens LA. Clinical experience with icodextrin in children:ultrafiltration profiles and metabolism. Pediatr Nephrol 2000; 15: 21-24.
62. Guo A, Wolfson M, Holt R. Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney Int Suppl 2002; 2002: S72-S79.
63. Johnson DW, Arndt M, O'Shea A, Watt R, Hamilton J, Vincent K. Icodextrin as salvage therapy for peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2002; 2002: 2.
64. Wilkie ME, Plant MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure:extension of CAPD technique survival. Perit Dial Int 1997; 17: 84-87.
65. Peers EM, Scrimgeour AC, Haycox AR. Cost-containment in CAPD patients with ultrafiltration failure. Clin Drug Invest 1995; 10: 53-58.
66. Dawnay AB, Millar DJ. Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int 1997; 17: 52-58.
67. de Fijter CW, Verbrugh HA, Oe LP, Heezius E, Donker AJ, Verhoef J et al. Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993; 21: 411-418.
68. Krediet RT, Douma CE, Ho dac Pannekeet MM, Imholz AL, Zemel D, Zweers MM et al. Impact of different dialysis solutions on solute and water transport. Perit Dial Int 1997; 17(Suppl 2): S17-S26.
69. Krediet RT, Ho-dac-Pannekeet MM, Imholz AL, Struijk DG. Icodextrin's effects on peritoneal transport. Perit Dial Int 1997; 17: 35-41.
70. Posthuma N, ter Wee P, Donker AJ, Dekker HA, Oe PL, Verbrugh HA. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Perit Dial Int 1999; 19: 334-342.
71. Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 2000; 15: 862-866.
72. Posthuma N, Verbrugh HA, Donker AJ, van Dorp W, Dekker HA, Peers EM et al. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Perit Dial Int 2000; 20: 174-180.
73. Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA. Assessment of the effectiveness, safety, and biocompatibilityoficodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int 2000; 20(Suppl 2): S106-S113.
74. Wens R, Taminne M, Devriendt J, Collart F, Broeders N, Mestrez F et al. A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer. Perit Dial Int 1998; 18: 603-609.
75. Li FK, Chan LY, Woo JC, Ho SK, Lo WK, Lai KN et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003; 42: 173-183.
76. Misra M, Ashworth J, Reaveley DA, Muller B, Brown EA. Nutritional effects of amino acid dialysate (Nutrineal) in CAPD patients. Adv Perit Dial 1996; 12: 311-314.
77. Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution:results of amulticenter outpatient study. Am J Kidney Dis 1998; 32: 761-769.
78. Tjiong HL, van den Berg JW, Wattimena JL, Rietveld T, van Dijk LJ, van der Wiel AM et al. Dialysate as food:combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005; 16: 1486-1493.
79. Qamar IU, Levin L, Balfe JW, Balfe JA, Secker D, Zlotkin S. Effects of 3-month amino acid dialysis compared to dextrose dialysis in children on continuous ambulatory peritoneal dialysis. Perit Dial Int 1994; 14: 34M1.
80. Qamar IU, Secker D, Levin L, Balfe JA, Zlotkin S, Balfe JW. Effects of amino acid dialysis compared to dextrose dialysis in children on continuous cycling peritoneal dialysis. Perit Dial Int 1999; 19: 237-247.
81. Selby NM, Fonseca S, Hulme L, Fluck RJ, Taal MW, McIntyre CW. Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodex-trin. Nephrol Dial Transplant 2005; 20: 1848-1853.
82. Van Biesen W, Boer W, De Greve B, Dequidt C, Vijt D, Faict D et al. A randomized clinical trialwith a 0.6% amino acid/1.4% glycerol peritoneal dialysis solution. Perit Dial Int 2004; 24: 222-230.